PROMISE队列中他汀类药物治疗与胰岛素敏感性和β细胞功能的纵向关联
PROMISE队列纳入498名2型糖尿病风险成人,随访9年,169人接受他汀(主要为瑞舒伐他汀和阿托伐他汀)。调整代谢危险因素后,他汀使用者胰岛素敏感性降低5.32%-6.36%、β细胞功能降低4.93%-7.59%(P < .001)。作者认为他汀与胰岛素敏感性和β细胞功能降低相关,且不同他汀和性别间可能存在差异。
要点
- 9年随访中169/498名参与者接受他汀,主要为瑞舒伐他汀和阿托伐他汀。
- 调整代谢危险因素后,他汀使用者胰岛素敏感性降低5.32%-6.36%、β细胞功能降低4.93%-7.59%(P < .001)。
- 瑞舒伐他汀与胰岛素敏感性和β细胞功能降低相关,阿托伐他汀与β细胞功能和胰岛素敏感性呈中等程度负相关。
核心结论
- 他汀治疗与胰岛素敏感性和β细胞功能降低相关,且不同他汀药物和性别间可能存在差异效应。
研究设计与样本
- PROMISE队列是一项针对2型糖尿病风险成人的纵向研究,使用基线和9年内3次随访访视的数据。
- 共498名参与者,年龄50岁,74%为女性;9年间169人接受他汀,以瑞舒伐他汀和阿托伐他汀为主。
- 他汀使用为自我报告,通过广义估计方程分析他汀与代谢标志物变化的关联。
主要发现
- 与未接受他汀治疗者相比,他汀使用者胰岛素敏感性降低5.32%-6.36%、β细胞功能降低4.93%-7.59%(P < .001),已调整代谢危险因素。
- 瑞舒伐他汀与胰岛素敏感性和β细胞功能降低相关,阿托伐他汀与β细胞功能和胰岛素敏感性呈中等程度负相关。
- 在女性参与者中,他汀降低胰岛素敏感性和β细胞功能;在男性参与者中仅β细胞功能改变。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Statin treatment lowers low-density lipoprotein (LDL) cholesterol, thereby reducing cardiovascular risk. Meta-analyses of clinical trials report a higher risk of new-onset type 2 diabetes with statins. Current clinical evidence regarding effects of statins on insulin sensitivity and beta-cell function is limited. OBJECTIVE: We examined the effects of statin treatment on longitudinal changes in early-risk phenotypes for type 2 diabetes. METHODS: The PROMISE cohort is a longitudinal study of adults at risk for type 2 diabetes. Data from baseline and 3 follow-up visits over 9 years were used to estimate insulin sensitivity (insulin sensitivity index, homeostatic model assessment for insulin sensitivity) and beta-cell function (insulinogenic index/homeostatic model assessment for insulin resistance, insulin secretion sensitivity index-2). Statin use was self-reported. Associations of statins with changes in metabolic markers were determined through generalized estimating equations. RESULTS: Over 9 years, 169 of 498 participants (aged 50 years, 74% female) received a statin, predominantly rosuvastatin and atorvastatin. Compared to those with no statin treatment, statin users had lower insulin sensitivity (5.32%-6.36%) and beta-cell function (4.93%-7.59%) (P < .001), adjusting for metabolic risk factors. Rosuvastatin was associated with decreased insulin sensitivity and beta-cell function, while atorvastatin showed moderate inverse association with beta-cell function and insulin sensitivity. In female participants, statins reduced insulin sensitivity and beta-cell function, while in male participants only beta-cell function was altered. CONCLUSION: Statin treatment was associated with lowered insulin sensitivity and beta-cell function with potential differential effects among statin agents and the sexes.
引用
- Lai KZH, Harris SB, Retnakaran R, et al. Longitudinal Association of Statin Treatment With Insulin Sensitivity and Beta-Cell Function in the PROMISE Cohort. J Clin Endocrinol Metab. 2025. PMID: 39820340. doi:10.1210/clinem/dgaf031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。